Neonc Technologies Holdings, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
NeOnc Technologies announced CEO stock purchases and updated Phase 2a results for its intranasal NEO100 drug, showing an increased objective response rate.
NASDAQ
NeOnc Technologies Holdings, Inc. announced its CEO purchased 80,000 shares and that the FDA granted a Type B End-of-Phase meeting to discuss accelerated approval for NEO100.
NASDAQ
NeOnc Technologies Holdings, Inc. announced positive Q3 2026 results, showcasing advancements in its NEO100 and NEO212 clinical programs, a $15 million capital raise, and a strategic MoU with Abu Dhabi.
NASDAQ
NeOnc Technologies announced upcoming presentations of data from its intranasal NEO100 and oral NEO212 programs at the 31st Annual Meeting of the Society for Neuro-Oncology.
NASDAQ
NeOnc Technologies reports early clinical improvement in a patient treated with NEO100 and signs a Memorandum of Understanding with the Department of Health Abu Dhabi.
NASDAQ
NeOnc Technologies announced the appointment of Ali Alabedin to its Board of Directors and that CEO Amir F. Heshmatpour will speak at the Abu Dhabi Future Health Summit.
NASDAQ
NeOnc Technologies Holdings, Inc. announced a scheduled End-of-Phase 1 meeting with the FDA on November 17, 2026, to discuss the development of its CNS cancer therapy, NEO212.
NASDAQ
NeOnc Technologies Holdings, Inc. has redeemed all outstanding shares of its Series A Convertible Preferred Stock for cash, simplifying its capital structure and eliminating potential dilution.
NASDAQ
NeOnc Technologies Holdings, Inc. reports significant open-market stock purchases by its CEO and Chief Medical Officer following positive Phase 2a results for its NEO100 therapy.
NASDAQ
NeOnc Technologies Holdings, Inc. announced the pricing of a registered direct offering of common stock and warrants, raising approximately $15 million.
NASDAQ
NeOnc Technologies Holdings, Inc. files an amendment to its Form 8-K to detail Nasim Shomali's appointment to the Audit Committee.
NASDAQ
NeOnc Technologies Holdings, Inc. reported the outcomes of its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.
NASDAQ
NeOnc Technologies announced positive top-line results from the Phase 2a portion of its NEO100-01 clinical trial for recurrent IDH1 mutant high-grade glioma, demonstrating a significant improvement in overall survival.
NASDAQ
NeOnc Technologies announced positive topline results from the Phase 2a portion of its NEO100-01 study, showing a significant improvement in progression-free survival for patients with recurrent IDH1-mutant glioma.
NASDAQ
NeOnc Technologies reported Q2 2026 financial results, confirmed topline data for its Phase 2a NEO100 study to be presented August 12, 2026, and announced international IND approvals.
NASDAQ
NeOnc Technologies Holdings, Inc. announced it received written feedback from the FDA regarding the CMC development program for its NEO212 drug candidate, including requirements for a capsule-to-tablet formulation transition.
NASDAQ
NeOnc Technologies Holdings, Inc. reports the resignation of a Class II director and the immediate appointment of a new director with extensive strategy and technology experience.
NASDAQ
NeOnc Technologies Holdings, Inc. has entered into a securities purchase agreement to raise up to $5 million through the issuance of Series A Convertible Preferred Stock.
NASDAQ
NeOnc Technologies Holdings, Inc. announced first quarter 2026 financial results, highlighting progress in its Phase 2 CNS cancer programs, a PIPE financing, and leadership appointments.
NASDAQ
NeOnc Technologies Holdings, Inc. has entered into a fourth securities purchase agreement to raise approximately $2 million to fund preclinical trials.
NASDAQ
CEO Amir Heshmatpour purchased $300,000 in company stock as NeOnc prepares for key clinical data readouts and FDA meetings.
NASDAQ
NeOnc Technologies Holdings, Inc. has entered into an Equity Distribution Agreement to sell up to $75 million of its common stock through an at-the-market offering.
NASDAQ
NeOnc Technologies Holdings, Inc. completed an initial closing of its third Securities Purchase Agreement, raising $1 million through the issuance of common stock and warrants.
NASDAQ
NeOnc Technologies announced positive dose-escalation results for its oral NEO212 therapy, establishing the Recommended Phase 2 Dose and showing early signs of clinical efficacy in CNS cancers.
NASDAQ
NeOnc Technologies Holdings, Inc. announced the full settlement of a legal dispute with Fox Infused, LLC, involving a payment of $737,920.77.
NASDAQ
NeOnc Technologies Holdings, Inc. announced the closing of an initial tranche of a new securities purchase agreement, raising $1.45 million for working capital.
NASDAQ
NeOnc Technologies Holdings, Inc. announced an investor conference call on March 4, 2026, to present initial Phase 1 dose-escalation data for its NEO212-01 clinical trial.
NASDAQ
NeOnc Technologies Holdings, Inc. announced an initial closing of a private placement, raising $10 million through the sale of common stock and warrants to an institutional investor.
NASDAQ
NeOnc Technologies announced updated clinical results for intranasal NEO100, showing significant long-term survival and radiographic remission in recurrent IDH1-mutant astrocytoma patients.
NASDAQ
NeOnc Technologies Holdings, Inc. announced a $1 million private placement of common stock and positive preclinical findings for its NEO100 therapeutic in combination with ultrasound for brain tumors.